BioNTech SE (NASDAQ:BNTX) Receives Average Rating of “Hold” from Analysts

BioNTech SE (NASDAQ:BNTX) has received a consensus rating of “Hold” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $120.40.

Several analysts have recently commented on BNTX shares. Oppenheimer started coverage on shares of BioNTech in a research report on Friday, January 5th. They set a “market perform” rating for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st. BMO Capital Markets cut their target price on BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a report on Thursday, March 21st. HC Wainwright cut their target price on BioNTech from $133.00 to $107.00 and set a “buy” rating on the stock in a report on Tuesday, January 23rd. Finally, The Goldman Sachs Group cut their target price on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 28th.

BioNTech Stock Performance

Shares of BNTX stock opened at $87.89 on Tuesday. The company has a market cap of $20.89 billion, a price-to-earnings ratio of 21.33 and a beta of 0.23. BioNTech has a 52 week low of $85.21 and a 52 week high of $129.10. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $91.86 and a 200-day moving average of $97.80.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. On average, equities analysts forecast that BioNTech will post -1.67 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Several large investors have recently bought and sold shares of the stock. Wealthcare Advisory Partners LLC bought a new position in BioNTech during the 1st quarter valued at $242,000. Park Avenue Securities LLC bought a new position in BioNTech during the 1st quarter valued at $201,000. American National Bank bought a new position in BioNTech during the 1st quarter valued at $81,000. Green Alpha Advisors LLC raised its stake in shares of BioNTech by 12.9% during the 1st quarter. Green Alpha Advisors LLC now owns 5,819 shares of the company’s stock worth $537,000 after purchasing an additional 666 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the period. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.